University Hospital Southampton NHS Foundation Trust, E Level, Tremona Road, Southampton, SO166YD, UK.
Hepatobiliary Surgery, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.
Surg Endosc. 2018 Feb;32(2):617-626. doi: 10.1007/s00464-017-5711-x. Epub 2017 Jul 17.
Evidence on the value of laparoscopic liver resections (LLR) for hepatocellular carcinoma (HCC) and severe cirrhosis is still lacking. The aim of this study is to assess surgical and oncological outcomes of LLR in cirrhotic HCC patients.
The analysis included 403 LLR for HCC from seven European centres. 333 cirrhotic and 70 non-cirrhotic patients were compared. A matched comparison was performed between 100 Child-Pugh A and 25 Child-Pugh B patients.
There was no difference in blood loss (250 vs. 250 mL, p 0.465) and morbidity (28.6 vs. 26.4%, p 0.473) between cirrhotics and non-cirrhotics, and liver-specific complications were similar (12.8 vs. 12%, p 0.924). The sub-analysis revealed similar perioperative outcomes in either Child-Pugh A or B patients. Noteworthy, ascitis (11 vs. 12%, p 0.562) and liver failure (3 vs. 4%, p 0.595) were not different. ASA score (OR 1.76, p 0.034) and conversion (OR 2.99, p 0.019) were risk factors for major morbidity. Despite lower recurrence-free survival in cirrhotics (43 vs. 55 months, p 0.034), overall survival was similar to non-cirrhotic patients (84 vs. 76.5, p 0.598).
LLR for HCC appear equally safe in cirrhotic and non-cirrhotic patients, and the advantages can be witnessed in those with advanced cirrhosis. Severe comorbidities and conversion should be considered risk factors for complications-rather than the severity of cirrhosis and portal hypertension-when liver resection is performed laparoscopically. Such results may be of great interest to liver surgeons and hepatologists when deciding on the management of HCC within cirrhosis.
腹腔镜肝切除术(LLR)治疗肝细胞癌(HCC)和严重肝硬化的价值仍缺乏证据。本研究旨在评估 LLR 治疗肝硬化 HCC 患者的手术和肿瘤学结果。
分析纳入了来自欧洲 7 个中心的 403 例 HCC 的 LLR。比较了 333 例肝硬化和 70 例非肝硬化患者。对 100 例 Child-Pugh A 级和 25 例 Child-Pugh B 级患者进行了匹配比较。
肝硬化组和非肝硬化组的术中出血量(250 与 250ml,p=0.465)和发病率(28.6%与 26.4%,p=0.473)无差异,肝特异性并发症相似(12.8%与 12%,p=0.924)。亚组分析显示,Child-Pugh A 级或 B 级患者的围手术期结果相似。值得注意的是,腹水(11%与 12%,p=0.562)和肝功能衰竭(3%与 4%,p=0.595)无差异。ASA 评分(OR 1.76,p=0.034)和中转开腹(OR 2.99,p=0.019)是严重并发症的危险因素。尽管肝硬化患者的无复发生存率较低(43 与 55 个月,p=0.034),但总体生存率与非肝硬化患者相似(84 与 76.5,p=0.598)。
LLR 治疗 HCC 在肝硬化和非肝硬化患者中同样安全,在晚期肝硬化患者中可以看到优势。严重的合并症和中转开腹应被视为并发症的危险因素,而不是肝硬化和门静脉高压的严重程度,当腹腔镜下进行肝切除术时。这些结果可能会引起肝外科医生和肝脏病学家的极大兴趣,他们在决定肝硬化合并 HCC 的管理时可以参考这些结果。